levosimendan 2.5 mg/ml concentrate for solution for infusion
as kalceks - levosimendan - concentrate for solution for infusion - levosimendan
levosimendan altan 2.5 mg/ml inf. sol. (conc.) i.v. vial
altan pharma ltd. - levosimendan 2,5 mg/ml - concentrate for solution for infusion - 2,5 mg/ml - levosimendan 2.5 mg/ml - levosimendan
levosimendan kabi 2.5 mg/ml inf. sol. (conc.) i.v. vial
fresenius kabi sa-nv - levosimendan 2,5 mg/ml - concentrate for solution for infusion - 2,5 mg/ml - levosimendan 2.5 mg/ml - levosimendan
levosimendan kalceks 2.5 mg/ml inf. sol. (conc.) i.v. vial
as kalceks a.s. - levosimendan 2,5 mg/ml - concentrate for solution for infusion - 2,5 mg/ml - levosimendan 2.5 mg/ml - levosimendan
simdax 2.5 mgml
bio-med - j.r ltd, israel - levosimendan - concentrate for solution for infusion - levosimendan 2.5 mg/ml - levosimendan - levosimendan - therapeutic indications: short-term treatment of acutely decompensated severe chronic heart failure.simdax should only be used as add-on therapy in situations where conventional therapy with e.g. diuretics, ace-inhibitors and digitalis is not sufficient and where there is a need for inotropic support.
levosimendan richet 12.5 mg polvo liofilizado para solución inyectable, i.v.
laboratorios richet, s.a. - levosimendan - levosimendan....12,50 mg / alcohol absoluto....5,00 ml
levosimendan advz
boucher & muir (nz) ltd t/a mercury pharma (nz) - levosimendan 2.5 mg/ml - concentrate for injection - 2.5 mg/ml - active: levosimendan 2.5 mg/ml excipient: citric acid ethanol povidone - levosimendan advz is indicated for the short-term treatment of acutely decompensated chronic heart failure (adhf) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate.
simdax
orion pharma (nz) limited - levosimendan 2.5 mg/ml - concentrate for infusion - 2.5 mg/ml - active: levosimendan 2.5 mg/ml excipient: citric acid ethanol povidone - simdax is indicated for the short-term treatment of acutely decompensated chronic heart failure (adhf) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate.
simdax 2.5 mg/ml inf. sol. (conc.) i.v. vial
orion corp. - levosimendan 2,5 mg/ml - concentrate for solution for infusion - 2,5 mg/ml - levosimendan 2.5 mg/ml - levosimendan
levosimendan tillomed 2,5 mg/ml konzentrat zur herstellung einer infusionslösung